New Vaccine-Immunotherapy combo targets multiple cancers in early trial
NCT ID NCT02432963
First seen Jan 31, 2026 · Last updated Jun 23, 2026 · Updated 19 times
Summary
This phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidney, melanoma, bladder, sarcoma, triple-negative breast, colorectal, and pancreatic cancers that have not responded to prior treatments. The main goal is to check safety and side effects, and to see if the combination can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
p53MVA vaccine and pembrolizumab (Keytruda)
What this could lead to
If it works, this could point toward a new treatment option for several hard-to-treat cancers that have stopped responding to other therapies.
What could go wrong
This is a very early, small phase 1 trial with only 11 participants, so safety and effectiveness are not yet proven. The vaccine uses a modified virus, which may cause side effects, and the combination may not work for all cancer types.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.